ニュースHetero Labs partners with MedicinesPatentPool.Hetero entered into a non-exclusive voluntary licensing agreement with Medicines Patent Pool (MPP) for manufacturing and sale of a generic version of Pfizer's COVID-19 oral antiviral treatment candidate nirmatrelvir, which is co-packaged with ritonavir (nirmatrelvir; ritonavir), in LMICs.
ニュースHetero Labs invests into assets: manufacturing facility in the amount of $22.6M in Vemagal, India, Southern Asia, Asia.It also sold its manufacturing facility at Vemagal in Karnataka to Hetero Labs for Rs 180 crore.
ニュースHetero Labs is developing generic version of molnupiravir in India.Hetero is developing their own generic version of molnupiravir in India under a voluntary license agreement with Merck.
